Ovarian Cancer

A combination of avutometinib and defactinib has been granted priority review by the FDA for the treatment of KRAS-mutant recurrent low-grade serous ovarian cancer.

Niraparib plus dostarlimab with platinum-based chemotherapy achieved superior PFS, meeting the primary end point of the phase 3 FIRST-ENGOT-OV44 trial.

PARP inhibitors have changed the way we think about [managing] ovarian cancer,” Whitney Goldsberry, MD, said

Sacituzumab tirumotecan had antitumor activity in pretreated advanced endometrial and ovarian cancer, data showed.

The novel drug SHR-A1921 was safe and efficacious in patients with platinum-resistant ovarian cancer, according to phase 1 data.

The FDA has received a rolling new drug application (NDA) for avutometinib plus defactinib for the treatment of adult patients with recurrent low-grade serous ovarian cancer harboring KRAS mutations who have received at least 1 prior line of systemic therapy.

Adding IMNN-001 to perioperative chemotherapy enhanced overall survival in patients with newly diagnosed, advanced ovarian cancer.

Oncology nurses can utilize risk assessment to predict patients at increased risk for cisplatin-induced acute kidney injury.

Alpha-emitting radiopharmaceutical Radspherin receives a fast track designation from the FDA for peritoneal carcinomatosis from ovarian cancer.

An oncology nurse's experience with her mother's cancer and her own BRCA2 diagnosis shapes her approach to patient care.

A durvalumab-based combination followed by an olaparib-based maintenance therapy improved progression-free survival in newly diagnosed advanced ovarian cancer without BRCA1/2 mutations.

Progression-free survival and platinum chemoresistance may be predicted by tumor-stroma proportion in patients with high-grade serous ovarian cancer.

The ready-to-dilute formulation of Tepylute for breast and ovarian cancers can help to reduce prep time and provide more accurate dosing.

Compared with placebo, first-line rucaparib maintenance therapy maintained a PFS benefit at 4 years in newly diagnosed advanced ovarian cancer.

Patients with recurrent ovarian cancer did not derive a benefit from adding atezolizumab to chemotherapy and bevacizumab.

Adding retroperitoneal lymphadenectomy to cytoreductive surgery did not improve survival in advanced ovarian cancer.

Postmenopausal women who had undergone hysterectomy and received treatment with conjugated equine estrogen alone had an increased incidence of ovarian cancer and mortality rates.

Patients with platinum-resistant or -refractory epithelial ovarian cancer treated with olaparib plus cediranib did not experience improvements in PFS and OS compared with chemotherapy.

Further evidence strengthens the support of mirvetuximab soravtansine as a new standard of care for folate receptor-alpha—positive ovarian cancer resistant to platinum chemotherapy.

Compared with placebo, first-line niraparib maintenance was not linked with worsened health-related quality of life outcomes in patients with advanced ovarian cancer.

The FDA granted an orphan drug designation to avutometinib either alone or in combination with defactinib for recurrent low-grade serous ovarian cancer.

Patients with FIGO stage IV ovarian cancer did not experience additional complications or worse survival with HIPEC compared with those with stage III disease.

Patients with recurrent ovarian cancer with BRCA-mutated and/or BRCAness phenotype did not derive a survival benefit with trabectedin when compared with chemotherapy.

Patients with stage III epithelial ovarian cancer treated with hyperthermic intraperitoneal chemotherapy plus interval cytoreductive surgery had improved progression-free survival and overall survival.

FDA granted a fast-track designation to the TROP2-directed ADC BNT325/DB-1305 for the treatment of platinum-resistant ovarian epithelial, fallopian tube, or primary peritoneal cancer.

A priority review has been granted by the FDA to trastuzumab deruxtecan for the treatment of unresectable or metastatic HER2-positive advanced solid tumors.

RC88, a mesothelin-targeting antibody-drug conjugate, was granted a fast track designation from the FDA for the treatment of platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.

A new drug application for SH-105 has been accepted by the FDA to potentially treat patients with breast and ovarian cancer.

For patients with gynecologic cancer for whom platinum-based chemotherapy is no longer effective, antibody-drug conjugates are an exciting second-line option.

The FDA has granted priority review to mirvetuximab soravtansine for folate receptor α (FRα)–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.